Barclays started coverage on shares of SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. The firm set an “overweight” rating and a $13.00 price target on the stock. Barclays‘s price objective points to a potential upside of 235.92% from the company’s previous close.
A number of other equities analysts have also recently issued reports on SABS. Weiss Ratings reissued a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. Wall Street Zen lowered shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Chardan Capital raised their price target on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of SAB Biotherapeutics in a report on Monday, June 15th. Finally, Leerink Partners lifted their target price on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.
Read Our Latest Stock Analysis on SABS
SAB Biotherapeutics Stock Down 1.5%
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Equities analysts predict that SAB Biotherapeutics will post -1.19 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the business. Commodore Capital LP purchased a new position in SAB Biotherapeutics during the 3rd quarter valued at about $8,847,000. Simplify Asset Management Inc. purchased a new position in SAB Biotherapeutics in the 4th quarter worth approximately $779,000. Propel Bio Management LLC bought a new position in shares of SAB Biotherapeutics in the 4th quarter worth $2,442,000. Spruce Street Capital LP bought a new position in shares of SAB Biotherapeutics in the 4th quarter worth $8,222,000. Finally, Jefferies Financial Group Inc. purchased a new stake in SAB Biotherapeutics during the fourth quarter valued at about $2,170,000. 7.82% of the stock is owned by institutional investors.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.
The company’s lead programs are directed primarily at infectious diseases.
Read More
- Five stocks we like better than SAB Biotherapeutics
- Marathon Petroleum Is Back, But Cycles Still Matter
- The SpaceX Sell-Off May Be More Than a Market Overreaction
- Chevron’s Microsoft Deal Turns Natural Gas Into an AI Trade
- Why nVent Could Be a Long-Term AI Infrastructure Winner
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
